Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025
Enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release tablet for prophylaxis of HAE attacks, is progressing as planned; topline data anticipated in 2H2026
Initiated CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks
Data presented at recent medical congresses, including final outcomes from the completed open-label extension phase of the Phase 2 CHAPTER-1 study, reinforce the potential of deucrictibant to differentiate through its efficacy and safety profile
Strong financial position with cash and cash equivalents of €329 million as of September 30, 2025
Parabilis Medicines Receives FDA Fast Track Designation for FOG-001, the First and Only Direct Inhibitor of the β-catenin:TCF Interaction, for the Treatment of Desmoid Tumors
Milestone follows disclosure of compelling preliminary data presented at the ESMO Congress and the CTOS 2025 Annual Meeting showing clinically meaningful anti-tumor activity in desmoid tumors CAMBRIDGE, Mass., November 12, 2025 — Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced that the U.S. Food and […]